About Us
Senior Vice Chairman of the Board, Executive Director: Mr. Tse Ping
-
- Senior Vice Chairman of the Board, Executive Director: Mr. Tse Ping
- The founding Chairman of the Company, he is currently the Senior Vice Chairman of the Board, an Executive Director, and a member of the Executive Board Committee. Mr. Tse has over thirty years of extensive experience in investment and management in the Chinese pharmaceutical industry. He is currently the Chairman of Nanjing Chia Tai Tianqing, Jiangsu Chia Tai Fenghai, Jiangsu Chia Tai Qingjiang, and Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd. He is also the Senior Vice Chairman of Charoen Pokphand Group (CP Group), Chairman of CP Pharmaceutical Group, Chairman of Tianjin Chia Tai Feed Tech Co., Ltd., and a director of Chia Tai Tianqing, Beijing Tide Pharmaceutical, Xinxing Energy Technology Co., Ltd., Chia Tai Overseas Chinese Real Estate Development Co., Ltd., and Chia Tai Qingchunbao Pharmaceutical Co., Ltd.
Soon after the adoption of the open-up and reform policy by China, Mr. Tse started to develop his investment and business in China. Starting in 1991, he entered the pharmaceutical industry, successively investing in over a dozen enterprises through equity participation and holding, becoming one of the most accomplished overseas investors in China's pharmaceutical industry. Today, the CP Pharmaceutical Group led by Mr. Tse has developed into a large, comprehensive, and group-based life and health industry enterprise. Its Hong Kong-listed company, Sino Biopharmaceutical Limited, is a constituent stock of the Hang Seng Index and holds a leading position among Hong Kong pharmaceutical stocks, with several national key high-tech enterprises under its umbrella.
The Group adheres to the concept of technological innovation, is based on an R&D system that combines innovative and generic drugs, and insists on developing world-class, cutting-edge biologics and innovative drugs. It continuously makes breakthroughs in multiple related fields such as medical services, medical devices, big health, and investment and M&A, and has become an innovative life and health industry group enterprise that covers the entire industry chain from drug R&D, manufacturing, and sales to chronic disease management and healthcare. Since its establishment, the Company has continuously broken historical records for revenue and net profit. It was selected as one of Forbes' "Asia's Fab 50" for three consecutive years from 2016 to 2018. It has been ranked on the "Top 50 Global Pharmaceutical Companies" list by the US magazine Pharm Exec for seven consecutive years from 2019 to 2025.
In recognition of his contributions to promoting the development of China's pharmaceutical industry, Mr. Tse has received several personal honors: In January 2008, he was awarded the "World Outstanding Chinese Award" and received an honorary doctorate from the University of West Alabama; in December 2008, he was granted the title of "2007/2008 Asian Knowledge Management Association Fellow" by the Asian Knowledge Management Association. Mr. Tse served as a member of the 9th, 10th, and 11th National Committees of the CPPCC. He is currently the Executive Vice President of the China Federation of Overseas Chinese Entrepreneurs and a Distinguished Professor at the University for Peace.
